Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

PubWeight™: 0.93‹?›

🔗 View Article (PMC 2377412)

Published in J Immunol on January 01, 2007

Authors

Anahit Ghochikyan1, Mikayel Mkrtichyan, Dmitri Loukinov, Gregory Mamikonyan, Svetlana D Pack, Nina Movsesyan, Thomas E Ichim, David H Cribbs, Victor V Lobanenkov, Michael G Agadjanyan

Author Affiliations

1: Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.

Articles citing this

Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res (2007) 1.23

BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer (2008) 1.20

DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther (2009) 1.13

BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res (2010) 1.04

The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One (2010) 1.02

Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med (2011) 0.90

BORIS, brother of the regulator of imprinted sites, is aberrantly expressed in hepatocellular carcinoma. Genet Test Mol Biomarkers (2012) 0.82

BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Cancer Immun (2013) 0.81

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy. Oncotarget (2016) 0.81

Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia (2012) 0.79

Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer. Sci Rep (2017) 0.78

Articles cited by this

Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61

Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (1987) 13.03

CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature (2000) 12.97

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73

Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 9.84

Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72

Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol (1990) 7.93

CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet (2001) 6.80

M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 6.61

An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell Biol (1996) 5.74

Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09

The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78

Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell (2003) 4.50

A novel sequence-specific DNA binding protein which interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5'-flanking sequence of the chicken c-myc gene. Oncogene (1990) 3.96

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59

CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus. Nat Genet (2001) 2.93

A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A (2004) 2.70

The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol (2002) 2.66

BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A (2002) 2.62

Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res (2002) 2.52

DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res (2005) 2.08

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood (1997) 1.96

A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer (1998) 1.79

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res (2005) 1.74

Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56

Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet (2003) 1.54

Flow cytometric measurement of intracellular cytokines. J Immunol Methods (2000) 1.47

Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker. Mol Cell Biol (2005) 1.43

Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF. Cancer Res (2001) 1.42

CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res (2005) 1.27

CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells. Proc Natl Acad Sci U S A (2003) 1.23

Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol (2005) 1.20

Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J Immunol (1999) 1.16

Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07

The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect (2003) 1.05

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res (2005) 0.99

Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. J Immunol (1994) 0.96

Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res (1996) 0.93

Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol (2003) 0.93

Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol (2001) 0.93

Cancer vaccines: pessimism in check. Nat Med (2004) 0.91

Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs. Semin Oncol (2005) 0.90

Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. Cancer Immun (2002) 0.89

Immune tolerance in breast cancer. Breast Dis (2004) 0.88

Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunol Cell Biol (2002) 0.87

Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination. Int J Cancer (1998) 0.86

Tumor antigens and tumor antigen discovery. Cancer Treat Res (2005) 0.83

Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect (2003) 0.82

Host resistance to Listeria monocytogenes infection is enhanced but resistance to Staphylococcus aureus infection is reduced in acute graft-versus-host disease in mice. Infect Immun (2000) 0.80

Mechanisms of abnormal gene expression in tumor cells. EXS (2006) 0.80

Assessment of lymphocyte-mediated cytotoxicity using flow cytometry. Methods Mol Biol (2004) 0.79

Recent advances in multiple myeloma immunotherapy. Biomed Pharmacother (2002) 0.77

Articles by these authors

Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature (2009) 24.41

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73

Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell (2007) 16.66

A map of the cis-regulatory sequences in the mouse genome. Nature (2012) 8.74

A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods (2005) 7.62

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52

The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol (2002) 2.66

BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A (2002) 2.62

Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res (2002) 2.52

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33

Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29

Endometrial regenerative cells: a novel stem cell population. J Transl Med (2007) 2.19

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res (2005) 2.08

CTCF interacts with and recruits the largest subunit of RNA polymerase II to CTCF target sites genome-wide. Mol Cell Biol (2007) 2.07

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02

Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis (2005) 1.93

Patterned cell culture inside microfluidic devices. Lab Chip (2004) 1.89

Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem (2002) 1.81

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res (2005) 1.74

Microfluidic Multicompartment Device for Neuroscience Research. Langmuir (2003) 1.72

Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72

Dynamic chromatin states in human ES cells reveal potential regulatory sequences and genes involved in pluripotency. Cell Res (2011) 1.72

Chromatin architecture near a potential 3' end of the igh locus involves modular regulation of histone modifications during B-Cell development and in vivo occupancy at CTCF sites. Mol Cell Biol (2005) 1.66

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med (2009) 1.62

Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation. Hum Mol Genet (2005) 1.60

Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation (2009) 1.60

Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood (2011) 1.58

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56

Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49

Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J (2011) 1.49

Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene (2002) 1.45

Polycystic ovary syndrome: focus on platelets and prothrombotic risk. South Med J (2011) 1.44

Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker. Mol Cell Biol (2005) 1.43

Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42

Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol (2003) 1.41

Malignant melanoma in pigmented skin: does the current interventional model fit a different clinical, histologic, and molecular entity? Dermatol Surg (2013) 1.41

Allele-specific binding of CTCF to the multipartite imprinting control region KvDMR1. Mol Cell Biol (2007) 1.40

Genome wide ChIP-chip analyses reveal important roles for CTCF in Drosophila genome organization. Dev Biol (2009) 1.39

Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38

Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36

Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. Report of four cases. J Neurosurg (2002) 1.35

Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31

Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30

Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis (2007) 1.28

CTCF binds the proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res (2005) 1.27

Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? J Transl Med (2008) 1.27

CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells. Proc Natl Acad Sci U S A (2003) 1.23

Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res (2007) 1.23

Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing. Genome Res (2009) 1.22

A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17

Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12

Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 1.11

Feasibility investigation of allogeneic endometrial regenerative cells. J Transl Med (2009) 1.10

Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res (2007) 1.10

Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol Aging (2012) 1.10

Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med (2010) 1.09

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett (2003) 1.09

Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09

Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08

ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07

Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest (2003) 1.07

Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 1.06

A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood (2009) 1.04

BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells. Nucleic Acids Res (2010) 1.04

Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03

Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis (2003) 1.03

Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03

Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02

Identification and characterization of SSTK, a serine/threonine protein kinase essential for male fertility. Mol Cell Biol (2005) 1.02

Evolutionary diversification of SPANX-N sperm protein gene structure and expression. PLoS One (2007) 1.02

The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One (2010) 1.02